DaVita Inc., formerly DaVita HealthCare Partners Inc., operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support. Its DMG division is a patient- and physician-focused integrated healthcare delivery and management company that provides medical services to members through capitation contracts. Its segments include U.S. dialysis and related lab services, DMG, and Other-Ancillary services and strategic initiatives. Its U.S. dialysis and related lab services line of business provide kidney dialysis services in the United States for patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). As of December 31, 2016, it had operated or provided administrative services to 154 outpatient dialysis centers.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Healthcare Facilities & Services - NEC
- Sub-Industry: Health Care Services
- Symbol: NYSE:DVA
- CUSIP: 23918K10
- Web: www.davita.com
Capitalization:- Market Cap: $12.92534 billion
- Outstanding Shares: 194,600,000
Average Prices:- 50 Day Moving Avg: $64.83
- 200 Day Moving Avg: $66.03
- 52 Week Range: $54.50 - $78.40
P/E:- Trailing P/E Ratio: 10.80
- Foreward P/E Ratio: 17.26
- P/E Growth: 1.61
Sales & Book Value:- Annual Revenue: $14.85 billion
- Price / Sales: 0.86
- Book Value: $26.41 per share
- Price / Book: 2.49
Profitability:- EBIDTA: $2.46 billion
- Net Margins: 8.28%
- Return on Equity: 14.85%
- Return on Assets: 3.97%
Debt:- Debt-to-Equity Ratio: 1.67%
- Current Ratio: 1.64%
- Quick Ratio: 1.57%
Misc:- Average Volume: 1.47 million shs.
- Beta: 0.89
- Short Ratio: 2.66
Frequently Asked Questions for DaVita HealthCare Partners (NYSE:DVA)
What is DaVita HealthCare Partners' stock symbol?
DaVita HealthCare Partners trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."
How were DaVita HealthCare Partners' earnings last quarter?
DaVita HealthCare Partners Inc. (NYSE:DVA) issued its quarterly earnings data on Tuesday, May, 2nd. The company reported $0.79 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.82 by $0.02. The business earned $3.70 billion during the quarter, compared to the consensus estimate of $3.69 billion. DaVita HealthCare Partners had a net margin of 8.28% and a return on equity of 14.85%. View DaVita HealthCare Partners' Earnings History.
When will DaVita HealthCare Partners make its next earnings announcement?
Where is DaVita HealthCare Partners' stock going? Where will DaVita HealthCare Partners' stock price be in 2017?
10 brokers have issued twelve-month price objectives for DaVita HealthCare Partners' stock. Their forecasts range from $62.00 to $75.00. On average, they expect DaVita HealthCare Partners' share price to reach $68.67 in the next twelve months. View Analyst Ratings for DaVita HealthCare Partners.
Who are some of DaVita HealthCare Partners' key competitors?
Some companies that are related to DaVita HealthCare Partners include Laboratory Corporation of America Holdings (LH), Quest Diagnostics Incorporated (DGX), Universal Health Services (UHS), Mednax (MD), NMC Health PLC (NMC), Acadia Healthcare Company (ACHC), HealthSouth Corporation (HLS), Molina Healthcare (MOH), Chemed Corp. (CHE), LifePoint Health (LPNT), Select Medical Holdings Corporation (SEM), Udg Healthcare PLC (UDG), Tenet Healthcare Corporation (THC), HMS Holdings Corp (HMSY), Community Health Systems (CYH), Kindred Healthcare (KND), HealthStream (HSTM) and China Cord Blood Corporation (CO).
Who are DaVita HealthCare Partners' key executives?
DaVita HealthCare Partners' management team includes the folowing people:
- Kent J. Thiry, Chairman of the Board
- James K. Hilger, Interim Chief Financial Officer, Chief Accounting Officer
- Joel Ackerman, Chief Financial Officer
- Robert Lang, President, International Business
- Javier J. Rodriguez, Chief Executive Officer - Kidney Care
- Jeanine M. Jiganti, Chief Compliance Officer
- LeAnne M. Zumwalt, Group Vice President - purchasing and government affairs
- Michael D. Staffieri, Chief Operating Officer- Kidney Care
- Kathleen Alyce Waters, Chief Legal Officer
- Peter T. Grauer, Lead Director, Independent Director
Who owns DaVita HealthCare Partners stock?
DaVita HealthCare Partners' stock is owned by a number of of institutional and retail investors. Top institutional investors include Founders Capital Management LLC (0.05%), Aperio Group LLC (0.04%), Exxonmobil Investment Management Inc. TX (0.02%), Investment House LLC (0.01%), Mn Services Vermogensbeheer B.V. (0.01%) and Deane Retirement Strategies Inc. (0.01%). Company insiders that own DaVita HealthCare Partners stock include Carol Anthony Davidson, Charles Berg, Dennis Kogod, James K Hilger, Javier Rodriguez, Jeanine Marie Jiganti, John M Nehra, Kent J Thiry, Kim M Rivera, Laura Mildenberger, Leanne M Zumwalt, Michael David Staffieri, Pamela M Arway, Roger Valine and William L Roper. View Institutional Ownership Trends for DaVita HealthCare Partners.
Who sold DaVita HealthCare Partners stock? Who is selling DaVita HealthCare Partners stock?
DaVita HealthCare Partners' stock was sold by a variety of institutional investors in the last quarter, including Investment House LLC, Aperio Group LLC, Exxonmobil Investment Management Inc. TX, Oakbrook Investments LLC, Xact Kapitalforvaltning AB and Smith Shellnut Wilson LLC ADV. Company insiders that have sold DaVita HealthCare Partners stock in the last year include Charles Berg, Javier Rodriguez, Michael David Staffieri and William L Roper. View Insider Buying and Selling for DaVita HealthCare Partners.
Who bought DaVita HealthCare Partners stock? Who is buying DaVita HealthCare Partners stock?
DaVita HealthCare Partners' stock was acquired by a variety of institutional investors in the last quarter, including Mn Services Vermogensbeheer B.V., Deane Retirement Strategies Inc., Founders Capital Management LLC and Eqis Capital Management Inc.. View Insider Buying and Selling for DaVita HealthCare Partners.
How do I buy DaVita HealthCare Partners stock?
Shares of DaVita HealthCare Partners can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DaVita HealthCare Partners' stock price today?
One share of DaVita HealthCare Partners stock can currently be purchased for approximately $65.76.
MarketBeat Community Rating for DaVita HealthCare Partners (NYSE DVA)MarketBeat's community ratings are surveys of what our community members think about DaVita HealthCare Partners and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for DaVita HealthCare Partners (NYSE:DVA) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 7 Hold Ratings, 2 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.10) |
| Consensus Price Target: | $68.67 (4.42% upside) |
Analysts' Ratings History for DaVita HealthCare Partners (NYSE:DVA)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 6/26/2017 | Jefferies Group LLC | Downgrade | Buy -> Hold | $64.89 -> $70.00 | Low |  |
| 5/25/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Sell | $62.00 | High | |
| 2/17/2017 | Royal Bank Of Canada | Reiterated Rating | Hold | $62.00 | N/A | |
| 12/13/2016 | Robert W. Baird | Downgrade | Outperform -> Neutral | $68.00 -> $69.00 | N/A | |
| 11/21/2016 | Bank of America Corporation | Reiterated Rating | Hold | $68.00 | N/A | |
| 11/1/2016 | Wells Fargo & Company | Reiterated Rating | Outperform | | N/A | |
| 10/13/2016 | SunTrust Banks, Inc. | Set Price Target | Hold | $66.00 | N/A | |
| 9/20/2016 | Raymond James Financial, Inc. | Upgrade | Market Perform -> Outperform | $75.00 | N/A | |
| 9/6/2016 | Citigroup Inc. | Initiated Coverage | Neutral | $71.00 | N/A | |
| 8/9/2016 | J P Morgan Chase & Co | Boost Price Target | Neutral | $74.00 -> $75.00 | N/A | |
| 4/6/2016 | Susquehanna Bancshares Inc | Boost Price Target | Neutral | $70.00 -> $78.00 | N/A | |
| 3/2/2016 | Sanford C. Bernstein | Lower Price Target | Market Perform | $74.50 -> $71.00 | N/A | |
| 2/12/2016 | William Blair | Reiterated Rating | Buy | | N/A | |
| 2/12/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $90.00 -> $85.00 | N/A | |
(Data available from 7/22/2015 forward)
Earnings History for DaVita HealthCare Partners (NYSE:DVA)Earnings History by Quarter for DaVita HealthCare Partners (NYSE DVA)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/1/2017 | | $0.90 | | | | | N/A | |
| 5/2/2017 | Q1 2017 | $0.82 | $0.79 | $3.69 billion | $3.70 billion | View | Listen | |
| 2/16/2017 | Q4 2016 | $0.91 | $0.98 | $3.74 billion | $3.72 billion | View | Listen | |
| 11/2/2016 | Q316 | $0.94 | $0.95 | $3.72 billion | $3.73 billion | View | Listen | |
| 8/8/2016 | Q216 | $0.98 | $1.01 | $3.67 billion | $3.72 billion | View | Listen | |
| 5/4/2016 | Q116 | $0.86 | $0.92 | $3.51 billion | $3.58 billion | View | Listen | |
| 2/11/2016 | Q415 | $0.97 | $1.01 | $3.50 billion | $3.53 billion | View | Listen | |
| 11/3/2015 | Q315 | $0.97 | $1.00 | $3.46 billion | $3.53 billion | View | Listen | |
| 8/4/2015 | Q215 | $0.95 | $0.95 | $3.37 billion | $3.43 billion | View | Listen | |
| 5/4/2015 | Q115 | $0.86 | $0.86 | $3.25 billion | $3.29 billion | View | Listen | |
| 2/12/2015 | Q414 | $0.89 | $0.96 | $3.26 billion | $3.33 billion | View | Listen | |
| 11/6/2014 | Q314 | $0.91 | $0.90 | $3.19 billion | $3.25 billion | View | Listen | |
| 7/31/2014 | Q214 | $0.88 | $0.95 | $3.10 billion | $3.17 billion | View | Listen | |
| 5/1/2014 | Q1 | $0.87 | $0.85 | $3.02 billion | $3.04 billion | View | Listen | |
| 2/11/2014 | Q413 | $1.91 | $0.99 | $2.92 billion | $3.06 billion | View | Listen | |
| 11/5/2013 | Q313 | $0.96 | $0.98 | $2.93 billion | $3.00 billion | View | Listen | |
| 8/6/2013 | Q2 2013 | $1.84 | $1.84 | $2.88 billion | $2.87 billion | View | Listen | |
| 5/7/2013 | Q1 2013 | $1.80 | $1.84 | $2.78 billion | $2.83 billion | View | Listen | |
| 2/14/2013 | Q4 2012 | $1.60 | $1.85 | $2.40 billion | $2.48 billion | View | Listen | |
| 10/30/2012 | | $1.55 | $1.56 | | | View | N/A | |
| 8/1/2012 | | $1.47 | $1.49 | | | View | N/A | |
| 2/16/2012 | | $1.49 | $1.58 | | | View | N/A | |
| 11/3/2011 | | $1.46 | $1.45 | | | View | N/A | |
| 8/3/2011 | | $1.14 | $1.17 | | | View | N/A | |
| 5/2/2011 | | $0.95 | $0.96 | | | View | N/A | |
| 2/10/2011 | | $1.12 | $0.70 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for DaVita HealthCare Partners (NYSE:DVA)2017 EPS Consensus Estimate: $3.53
2018 EPS Consensus Estimate: $3.85
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.77 | $0.84 | $0.81 |
| Q2 2017 | 3 | $0.90 | $0.92 | $0.91 |
| Q3 2017 | 3 | $0.89 | $0.97 | $0.93 |
| Q4 2017 | 3 | $0.80 | $0.92 | $0.88 |
| Q1 2018 | 2 | $0.87 | $0.88 | $0.88 |
| Q2 2018 | 2 | $0.99 | $1.02 | $1.01 |
| Q3 2018 | 2 | $1.01 | $1.02 | $1.02 |
| Q4 2018 | 2 | $0.89 | $1.01 | $0.95 |
(Data provided by Zacks Investment Research)
Dividend History for DaVita HealthCare Partners (NYSE:DVA)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for DaVita HealthCare Partners (NYSE:DVA)Insider Ownership Percentage: 2.10%
Institutional Ownership Percentage: 81.93%
Insider Trades by Quarter for DaVita HealthCare Partners (NYSE:DVA)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/15/2017 | Javier Rodriguez | CEO | Sell | 1,294 | $66.21 | $85,675.74 | |
| 5/9/2017 | Charles Berg | Director | Sell | 8,414 | $65.80 | $553,641.20 | |
| 5/4/2017 | William L Roper | Director | Sell | 12,994 | $65.89 | $856,174.66 | |
| 8/9/2016 | Michael David Staffieri | COO | Sell | 20,262 | $73.09 | $1,480,949.58 | |
| 7/11/2016 | Jeanine Marie Jiganti | Insider | Sell | 1,291 | $78.51 | $101,356.41 | |
| 7/1/2016 | Jeanine Marie Jiganti | Insider | Sell | 4,620 | $77.45 | $357,819.00 | |
| 5/25/2016 | Pamela M Arway | Director | Sell | 10,824 | $77.16 | $835,179.84 | |
| 5/23/2016 | James K Hilger | CFO | Sell | 3,416 | $76.79 | $262,314.64 | |
| 5/20/2016 | Kent J Thiry | CEO | Sell | 32,880 | $76.99 | $2,531,431.20 | |
| 5/17/2016 | Dennis Kogod | CEO | Sell | 17,700 | $77.35 | $1,369,095.00 | |
| 5/17/2016 | Leanne M Zumwalt | VP | Sell | 538 | $77.08 | $41,469.04 | |
| 5/16/2016 | James K Hilger | CFO | Sell | 3,983 | $75.59 | $301,074.97 | |
| 5/16/2016 | Javier Rodriguez | CEO | Sell | 36,466 | $75.44 | $2,750,995.04 | |
| 5/16/2016 | Michael David Staffieri | COO | Sell | 4,934 | $75.69 | $373,454.46 | |
| 5/12/2016 | Roger Valine | Director | Sell | 8,220 | $76.34 | $627,514.80 | |
| 5/10/2016 | Dennis Kogod | CEO | Sell | 40,048 | $76.25 | $3,053,660.00 | |
| 5/6/2016 | John M Nehra | Director | Sell | 16,314 | $75.56 | $1,232,685.84 | |
| 4/11/2016 | Javier Rodriguez | CEO | Sell | 89,912 | $73.51 | $6,609,431.12 | |
| 3/21/2016 | Dennis Kogod | CEO | Sell | 13,455 | $72.12 | $970,374.60 | |
| 2/29/2016 | Pamela M Arway | Director | Sell | 9,026 | $66.00 | $595,716.00 | |
| 2/23/2016 | Leanne M. Zumwalt | VP | Sell | 14,587 | $64.25 | $937,214.75 | |
| 2/16/2016 | Dennis Kogod | CEO | Sell | 33,290 | $61.99 | $2,063,647.10 | |
| 12/17/2015 | Laura Mildenberger | insider | Sell | 1,440 | $68.14 | $98,121.60 | |
| 9/22/2015 | Kim M. Rivera | insider | Sell | 40,037 | $75.48 | $3,021,992.76 | |
| 8/17/2015 | Carol Anthony Davidson | Director | Sell | 4,038 | $79.93 | $322,757.34 | |
| 6/4/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $83.39 | $2,618,446.00 | |
| 5/28/2015 | Michael David Staffieri | COO | Sell | 9,050 | $84.07 | $760,833.50 | |
| 5/19/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $83.22 | $1,306,554.00 | |
| 5/18/2015 | James K Hilger | CFO | Sell | 3,983 | $82.10 | $327,004.30 | |
| 5/18/2015 | Michael David Staffieri | COO | Sell | 2,047 | $82.03 | $167,915.41 | |
| 5/18/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $82.24 | $1,291,168.00 | |
| 5/11/2015 | James K Hilger | CFO | Sell | 8,267 | $82.00 | $677,894.00 | |
| 5/11/2015 | Jeanine Marie Jiganti | Insider | Sell | 2,481 | $81.95 | $203,317.95 | |
| 5/11/2015 | John M Nehra | Director | Sell | 12,278 | $81.85 | $1,004,954.30 | |
| 4/21/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $82.40 | $2,587,360.00 | |
| 4/7/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $82.15 | $1,289,755.00 | |
| 4/6/2015 | Robert J Margolis | Chairman | Sell | 15,700 | $81.49 | $1,279,393.00 | |
| 3/27/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $81.18 | $2,549,052.00 | |
| 3/12/2015 | Robert J Margolis | Chairman | Sell | 107,374 | $79.24 | $8,508,315.76 | |
| 2/27/2015 | Robert J Margolis | Chairman | Sell | 21,000 | $74.29 | $1,560,090.00 | |
| 2/19/2015 | Robert J Margolis | Chairman | Sell | 21,000 | $73.12 | $1,535,520.00 | |
| 1/30/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $75.48 | $2,370,072.00 | |
| 1/23/2015 | Michael David Staffieri | COO | Sell | 21,869 | $76.05 | $1,663,137.45 | |
| 1/16/2015 | Robert J Margolis | Chairman | Sell | 31,400 | $74.92 | $2,352,488.00 | |
| 1/8/2015 | Kim M Rivera | Insider | Sell | 1,111 | $75.10 | $83,436.10 | |
| 12/30/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $76.09 | $2,389,226.00 | |
| 12/29/2014 | Robert J Margolis | Chairman | Sell | 15,700 | $76.09 | $1,194,613.00 | |
| 12/19/2014 | Laura Mildenberger | Insider | Sell | 1,446 | $75.50 | $109,173.00 | |
| 12/18/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $74.67 | $2,344,638.00 | |
| 12/3/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $75.80 | $2,380,120.00 | |
| 12/1/2014 | Kim M Rivera | Insider | Sell | 6,503 | $76.08 | $494,748.24 | |
| 11/21/2014 | Robert J Margolis | Chairman | Sell | 31,400 | $75.08 | $2,357,512.00 | |
| 11/11/2014 | Kent J Thiry | CEO | Sell | 344,938 | $74.52 | $25,704,779.76 | |
| 11/11/2014 | Robert J Margolis | Chairman | Sell | 250,000 | $75.09 | $18,772,500.00 | |
| 11/10/2014 | Berkshire Hathaway Inc | Major Shareholder | Buy | 944,418 | $74.11 | $69,990,817.98 | |
| 11/7/2014 | R. Ted Weschler | Major Shareholder | Buy | 820,018 | $74.10 | $60,763,333.80 | |
| 11/3/2014 | Roger Valine | Director | Sell | 7,185 | $77.85 | $559,352.25 | |
| 9/16/2014 | John M Nehra | Director | Sell | 20,000 | $73.91 | $1,478,200.00 | |
| 9/8/2014 | Kim M Rivera | Insider | Sell | 1,111 | $74.25 | $82,491.75 | |
| 8/27/2014 | Leanne M Zumwalt | VP | Sell | 3,214 | $74.57 | $239,667.98 | |
| 8/11/2014 | Jeanine Marie Jiganti | Insider | Sell | 2,500 | $72.14 | $180,350.00 | |
| 6/11/2014 | Kim M Rivera | Insider | Sell | 5,929 | $71.05 | $421,255.45 | |
| 5/29/2014 | Laura Mildenberger | Insider | Sell | 5,080 | $69.99 | $355,549.20 | |
| 5/16/2014 | Dennis Kogod | COO | Sell | 18,750 | $67.30 | $1,261,875.00 | |
| 5/16/2014 | Kent Thiry | CEO | Sell | 17,600 | $67.41 | $1,186,416.00 | |
| 5/15/2014 | James Hilger | CAO | Sell | 1,666 | $67.23 | $112,005.18 | |
| 5/15/2014 | Javier Rodriguez | CEO | Sell | 7,000 | $67.50 | $472,500.00 | |
| 5/12/2014 | Dennis Kogod | COO | Sell | 32,188 | $68.06 | $2,190,715.28 | |
| 5/8/2014 | Dennis Kogod | COO | Sell | 32,213 | $67.36 | $2,169,867.68 | |
| 5/7/2014 | Michael David Staffieri | COO | Sell | 2,633 | $67.30 | $177,200.90 | |
| 4/2/2014 | Michael David Staffieri | COO | Sell | 2,867 | $69.15 | $198,253.05 | |
| 3/20/2014 | Laura Mildenberger | Insider | Sell | 3,274 | $70.04 | $229,310.96 | |
| 2/26/2014 | R. Ted Weschler | major shareholder | Buy | 1,159,858 | $66.97 | $77,675,690.26 | |
| 2/21/2014 | John Nehra | Director | Sell | 40,000 | $65.81 | $2,632,400.00 | |
| 2/18/2014 | William Roper | Director | Sell | 42,519 | $66.37 | $2,821,986.03 | |
| 12/20/2013 | Laura Mildenberger | Insider | Sell | 10,417 | $62.53 | $651,375.01 | |
| 12/17/2013 | Allen Nissenson | Insider | Sell | 2,929 | $59.83 | $175,242.07 | |
| 12/9/2013 | Berkshire Hathaway Inc | major shareholder | Buy | 1,314,170 | $57.84 | $76,011,592.80 | |
| 11/8/2013 | R. Ted Weschler | major shareholder | Buy | 3,700,294 | $55.14 | $204,034,211.16 | |
| 7/5/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 110,309 | $114.01 | $12,576,329.09 | |
| 7/3/2013 | R. Ted Weschler | Major Shareholder | Buy | 639,200 | $114.78 | $73,367,376.00 | |
| 5/15/2013 | David T Shapiro | Insider | Sell | 8,779 | $129.80 | $1,139,514.20 | |
| 5/15/2013 | Dennis Kogod | COO | Sell | 21,130 | $129.47 | $2,735,701.10 | |
| 5/15/2013 | James K Hilger | CFO | Sell | 1,049 | $130.18 | $136,558.82 | |
| 5/15/2013 | Leanne M Zumwalt | VP | Sell | 13,209 | $129.59 | $1,711,754.31 | |
| 5/13/2013 | Kent J Thiry | CEO | Sell | 243,307 | $129.95 | $31,617,744.65 | |
| 5/13/2013 | Kim M Rivera | Insider | Sell | 1,672 | $129.70 | $216,858.40 | |
| 3/4/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 164,947 | $119.59 | $19,726,011.73 | |
| 3/4/2013 | Roger Valine | Director | Sell | 1,390 | $120.00 | $166,800.00 | |
| 2/27/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 211,889 | $116.56 | $24,697,781.84 | |
| 2/22/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 224,091 | $115.88 | $25,967,665.08 | |
| 2/19/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 323,070 | $116.73 | $37,711,961.10 | |
| 2/5/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 32,376 | $115.17 | $3,728,743.92 | |
| 2/4/2013 | Roger Valine | Director | Sell | 1,389 | $116.13 | $161,304.57 | |
| 1/16/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 42,400 | $111.33 | $4,720,392.00 | |
| 1/15/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 179,300 | $109.67 | $19,663,831.00 | |
| 1/10/2013 | Berkshire Hathaway Inc | Major Shareholder | Buy | 187,898 | $109.54 | $20,582,346.92 | |
| 12/24/2012 | Dennis Kogod | COO | Sell | 12,736 | $111.00 | $1,413,696.00 | |
| 12/21/2012 | James K Hilger | CFO | Sell | 2,073 | $112.20 | $232,590.60 | |
| 12/6/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 635,633 | $106.20 | $67,504,224.60 | |
| 11/29/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 679,249 | $108.20 | $73,494,741.80 | |
| 11/26/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 412,050 | $110.38 | $45,482,079.00 | |
| 11/16/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 132,958 | $112.45 | $14,951,127.10 | |
| 11/12/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 548,823 | $112.15 | $61,550,499.45 | |
| 11/7/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 139,491 | $112.03 | $15,627,176.73 | |
| 11/2/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 254,750 | $112.20 | $28,582,950.00 | |
| 10/26/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 257,941 | $111.14 | $28,667,562.74 | |
| 10/17/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 63,928 | $109.56 | $7,003,951.68 | |
| 10/12/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 217,597 | $109.76 | $23,883,446.72 | |
| 10/9/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 67,946 | $107.71 | $7,318,463.66 | |
| 9/28/2012 | Berkshire Hathaway Inc | Major Shareholder | Buy | 282,403 | $102.03 | $28,813,578.09 | |
| 8/8/2012 | Kent J Thiry | Chairman | Sell | 320,877 | $96.88 | $31,086,563.76 | |
| 8/7/2012 | William L Roper | Director | Sell | 23,019 | $95.95 | $2,208,673.05 | |
(Data available from 1/1/2013 forward)
Headline Trends for DaVita HealthCare Partners (NYSE:DVA)
Latest Headlines for DaVita HealthCare Partners (NYSE:DVA)
| Source: |
|
| Date | Headline |
|---|
 | $3.83 Billion in Sales Expected for DaVita HealthCare Partners Inc. (DVA) This Quarter
www.americanbankingnews.com - July 19 at 12:21 PM |
 | DaVita, Inc. breached its 50 day moving average in a Bullish Manner : DVA-US : July 18, 2017
finance.yahoo.com - July 18 at 7:37 PM |
| DaVita HealthCare Partners Inc. (NYSE:DVA) Expected to Post Earnings of $0.90 Per Share
www.americanbankingnews.com - July 17 at 8:12 PM |
 | Longtime physician practice name disappears in Tampa Bay
www.bizjournals.com - July 17 at 6:59 PM |
| Reviewing DaVita HealthCare Partners (NYSE:DVA) and Laboratory Corporation of America Holdings (LH)
www.americanbankingnews.com - July 17 at 12:18 AM |
| DaVita Medical Group Buys Dr. Rahn Shaw Practices in Orlando
finance.yahoo.com - July 14 at 4:04 PM |
| DaVita HealthCare Partners Inc. (DVA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 11 at 5:34 PM |
| Davita Inc (DVA) Downgraded by BidaskClub
www.americanbankingnews.com - July 8 at 7:46 PM |
 | Robbins Arroyo LLP Investigates Whether DaVita Inc. (DVA) Misled Shareholders - Business Wire (press release)
www.businesswire.com - July 8 at 5:39 PM |
| Robbins Arroyo LLP Investigates Whether DaVita Inc. (DVA) Misled Shareholders
finance.yahoo.com - July 8 at 10:20 AM |
| DaVita Inc. Schedules 2nd Quarter 2017 Investor Conference Call
finance.yahoo.com - July 5 at 6:46 PM |
| DaVita HealthCare Partners Inc. (DVA) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - July 4 at 1:40 PM |
 | DaVita Medical Group Recognized for Excellence in Coordinated Care - PR Newswire (press release)
www.prnewswire.com - June 29 at 7:35 PM |
| DaVita Medical Group Recognized for Excellence in Coordinated Care
finance.yahoo.com - June 29 at 7:35 PM |
| Brokers Set Expectations for DaVita HealthCare Partners Inc.'s FY2017 Earnings (DVA)
www.americanbankingnews.com - June 28 at 8:02 AM |
| Morning Movers: Arconic Tumbles, DaVita Drops, Coach Rises
finance.yahoo.com - June 26 at 5:44 PM |
| Patient-Steering Allegations Only One Reason DaVita Shares Getting Downgraded
finance.yahoo.com - June 26 at 5:44 PM |
| DaVita HealthCare Partners Inc. (DVA) Stock Rating Lowered by Jefferies Group LLC
www.americanbankingnews.com - June 26 at 12:52 PM |
 | Investigation Relating to 401(k) Plans of DaVita Inc. (NYSE:DVA) Commenced by Stull, Stull & Brody
feeds.benzinga.com - June 23 at 8:59 PM |
| DaVita HealthCare Partners Inc. (DVA) Expected to Announce Quarterly Sales of $3.83 Billion
www.americanbankingnews.com - June 23 at 3:18 PM |
| Zacks: Brokerages Expect DaVita HealthCare Partners Inc. (DVA) Will Post Earnings of $0.90 Per Share
www.americanbankingnews.com - June 21 at 6:10 PM |
| Is DaVita a Suitable Stock for Value Investors?
finance.yahoo.com - June 20 at 5:32 PM |
| ETFs with exposure to DaVita, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 6:44 PM |
| Dr. David Mahoney Named Chief Medical Officer of Lifeline Vascular Access
finance.yahoo.com - June 19 at 1:42 PM |
| Health-Care Investors Are in Denial
finance.yahoo.com - June 16 at 5:38 PM |
| DBJ's best of the week for June 10-16: Inside the Amazon and ViaWest deals, hospital merger talks and more
finance.yahoo.com - June 16 at 5:38 PM |
| DaVita HealthCare Partners Inc. (DVA) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - June 16 at 12:50 PM |
| DaVita Clinical Research Launches Alliance Site Network for Early Stage CKD Trials
finance.yahoo.com - June 15 at 6:51 PM |
| DaVita Celebrates 10 Years of Sustainability
finance.yahoo.com - June 8 at 5:50 PM |
| ETFs with exposure to DaVita, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 5:50 PM |
| DaVita Introduces DaVita® Health Solutions
finance.yahoo.com - June 6 at 5:13 PM |
| DaVita, Inc. :DVA-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017
finance.yahoo.com - June 6 at 5:13 PM |
| Robbins Arroyo LLP: DaVita Inc. (DVA) Misled Shareholders According to a Class Action
finance.yahoo.com - June 6 at 5:13 PM |
| DaVita, Inc. breached its 50 day moving average in a Bullish Manner : DVA-US : June 2, 2017
finance.yahoo.com - June 2 at 4:15 PM |
| DBJ's best of the week for May 27-June 2: DaVita CEO's challenges, our money series and more
finance.yahoo.com - June 2 at 4:15 PM |
 | DaVita's (DVA) HealthCare Partners Announce Acquisition of Magan Medical Clinic - StreetInsider.com
www.streetinsider.com - June 2 at 3:33 AM |
| DaVita's (DVA) HealthCare Partners Announce Acquisition of Magan Medical Clinic
www.streetinsider.com - June 1 at 5:30 PM |
| HealthCare Partners to Acquire Magan Medical Clinic
finance.yahoo.com - June 1 at 5:30 PM |
| Dialysis Firms Get Help From Congress in Overturning Charity Ban
finance.yahoo.com - May 31 at 9:49 AM |
| Exclusive: DaVita CEO Kent Thiry, his journey from failure to success and the challenges he faces (Photos)
www.bizjournals.com - May 30 at 11:38 AM |
| Brokerages Anticipate Davita Inc (DVA) Will Announce Quarterly Sales of $3.83 Billion
www.americanbankingnews.com - May 28 at 9:08 AM |
| Jefferies Group LLC Analysts Give Davita Inc (DVA) a $70.00 Price Target
www.americanbankingnews.com - May 27 at 8:24 AM |
 | Commit To Purchase DaVita At $57.50, Earn 5.1% Annualized Using Options
www.nasdaq.com - May 26 at 5:25 PM |
| Zacks: Analysts Anticipate Davita Inc (DVA) to Announce $0.90 EPS
www.americanbankingnews.com - May 26 at 12:50 PM |
| DaVita Celebrates Military Appreciation Month
finance.yahoo.com - May 26 at 4:45 AM |
| DaVita (DVA) Shares Cross Above 200 DMA - Nasdaq
www.nasdaq.com - May 25 at 11:44 PM |
| DaVita adquiere Centrum Dializa II - PR Newswire - PR Newswire (Comunicado de prensa)
www.prnewswire.com - May 25 at 6:43 PM |
| DaVita acquires Polish dialysis company
finance.yahoo.com - May 25 at 6:43 PM |
| Davita Inc (DVA) Given Sell Rating at Goldman Sachs Group Inc
www.americanbankingnews.com - May 25 at 6:11 PM |
| DaVita Kidney Care Welcomes Eric Severson as Chief People Officer
finance.yahoo.com - May 24 at 12:29 PM |
DaVita HealthCare Partners (DVA) Chart for Saturday, July, 22, 2017
